

Vaccines, immune recovery and eradication

Thursday 18th October 2018

Caixa Forum
Av. de Francesc Ferrer i Guàrdia, 6-8
Barcelona - Spain

More information and registrations at: www.fls-science.com/eradication

With the collaboration and sponsorship of:









HIV infection remains a major public health threat worldwide. Around 37 million people are living with HIV and only 21.7 million were accessing antiretroviral treatment in 2017. Since the start of the epidemic 77.3 million have become infected and 35.4 million have died from AIDS-related illness. There are 1.7 million new HIV infections every year and it is estimated that 75% of the people living with HIV know their status, among those 79% are accessing treatment and 81% of those accessing treatment are virally suppressed.

\* UNAIDS Fact Sheet – July 2018 (www.unaids.org)

After more than 30 years researching on HIV, seems clear that the solution needs to come from the therapeutic cure, since preventative measures have proved to be insufficient to stop the epidemic and cure those who suffer from the infection. Research on HIV progresses rapidly and gives room for hope. At this moment the possibility of eradicating the virus or discover an effective vaccine are the two main strategic lines in the fight against the disease.

The yearly conference on *Hot topics in HIV: Vaccines, Immune Recovery and Eradication* responds to the need of providing an update on these issues, which have a direct impact on the current treatment strategies.

The meeting is addressed to researchers and physicians specialized in HIV and its aim is to provide an update on the latest findings in research on the different strategies of HIV eradication, establish links between these findings and its implications in the diagnosis and treatment of HIV+ patients and discuss with experts the basic research and clinical implications to be applied to the daily practice.

## Preliminary program



13.30-14.30	Registration and Networking Lunch	
14.30-14.45	Welcome	Xavier Martinez-Picado Group Lead Retrovirology and Clinical Studies at IrsiCaixa / ICREA research professor. Barcelona, Spain
14.45-15.10	Future goals of ART in HIV Cure	Daria Hazuda MSD Vice President, Infectious Disease & Vaccines, CSO Cambridge Exploratory Science Center. West Point, PA, USA
15.10-15.35	Reactivation of reservoirs	Martin Tolstrup Department of Infectious Diseases, Aarhus University Hospital. Aarhus, Denmark
15.35-16.00	Immuno based therapies and HIV eradication	Rafick-Pierre Sékaly Professor, Department of Pathology. Case Western Reserve University. Cleveland, USA
16.00-16.25	VLP – Virus-Like Particles role in HIV eradication	Julià Blanco Group Lead Cell Virology and Immunology at IrsiCaixa. Barcelona, Spain
16.25-16.45	Coffee break	
16.45-17.10	Combinational CRISPR/Cas9 gene-editing approach to halt HIV replication	Monique Nijhuis Group Lead Translational Virology at University Medical Center Utrecht, The Netherlands
17.10-17.35	The microbiome in HIV Immunopathogenesis	Roger Paredes Group Lead Microbial Genomics at IrsiCaixa. Barcelona, Spain
17.35-18.20	Clinical experiences on HIV remission in absence of ART	Facilitator  Bonaventura Clotet, IrsiCaixa Clinicians Mi Kwon, Department of Hematology. University Hospital Gregorio Marañón. Spain José Moltó, Fight AIDS Foundation. University Hospital Germans Trias y Pujol. Barcelona, Spain
18.20-18.45	Paving the way towards a world free of AIDS	Mario Stevenson Professor of Medicine and Infectious Diseases at the Miller School of Medicine. University of Miami. USA
		03/1